Lipoprotein Subpopulation Distributions in Lean, Obese, and Type 2 Diabetic Women: A Comparison of African and White Americans
|
|
- Eric Stanley Knight
- 5 years ago
- Views:
Transcription
1 Lipoprotein Subpopulation Distributions in Lean, Obese, and Type 2 Diabetic Women: A Comparison of African and White Americans Paul S. MacLean, Joseph F. Bower, Satyaprasad Vadlamudi, Thomas Green, and Hisham A. Barakat Abstract MACLEAN, PAUL S., JOSEPH F. BOWER, SATYAPRASAD VADLAMUDI, THOMAS GREEN, AND HISHAM A. BARAKAT. Lipoprotein subpopulation distributions in lean, obese, and type 2 diabetic women: a comparison of African and white Americans. Obes Res. 2000:8: Objective: Abnormal subpopulation distributions of plasma lipoproteins have been reported in white American (WA) women with obesity and type 2 diabetes that explain part of the elevated rate of cardiovascular disease in these patients. This study examined if these perturbations also occur in obese and diabetic African American (AA) women and compared the lipoprotein profiles with WA counterparts. Research Methods and Procedures: We determined the lipoprotein subpopulation distribution in the plasma of 51 lean women (29 WA, 22 AA, body mass index [BMI] 30), 50 obese women (27 WA, 23 AA, BMI 30), and 43 obese women with type 2 diabetes (27 WA, 16 AA), by nuclear magnetic resonance spectroscopy. Results: AA diabetic women, like WA diabetic women, had a larger average very low density lipoprotein (VLDL) size, elevated levels of small low density lipoprotein cholesterol (LDL-C), and lower levels of small high density lipoprotein cholesterol (HDL-C), when compared to lean controls (p 0.05). These differences were accompanied by higher VLDL-triglycerides (TG) and LDL-C in WA (p 0.05), but not in AA. Although the effects of obesity and diabetes on lipoprotein subpopulation were fairly similar for AA and WA, some racial differences, particularly with respect to HDL, were observed. Submitted for publication March 24, Accepted for publication in final form July 22, From the Department of Biochemistry, East Carolina University School of Medicine, Greenville, NC Address correspondence to Hisham Barakat, PhD, Department of Biochemistry, East Carolina University School of Medicine, Greenville, NC BARAKAT@ brody.med.ecu.edu Copyright 2000 NAASO. Discussion: The atherogenic perturbations in lipoprotein profiles of obese AA women, particularly those with diabetes, were relatively similar to those found in WA women and may be contributing to the increased rate of cardiovascular disease (CVD) in AA with obesity and diabetes. The parameters of subpopulation distribution may provide better markers for CVD than lipid concentrations alone, particularly in AA women. Furthermore, subtle racial differences in lipoprotein profiles suggest that race-specific criteria may be needed to screen patients for CVD. Key words: VLDL, LDL, HDL, NMR spectroscopy, CETP Introduction It is well established that the risk and incidence of cardiovascular disease (CVD) is related to alterations in the concentrations of plasma lipids and lipoproteins. The major features of this dyslipidemia shown to be associated with CVD are elevations in total and LDL cholesterol (TC, LDL-C), higher total triglycerides (TG), and a lower HDL cholesterol (HDL-C). In addition to the changes in plasma lipid concentrations, alterations in the chemical and physical characteristics of the lipoproteins, which cause shifts in the subpopulation distribution of these lipoproteins, have been shown to contribute to CVD risk. Small and dense LDL and large very low density lipoprotein (VLDL) particles have been shown to be more prevalent in the plasma of patients with heart disease (1 6). Furthermore, patients with CVD tend to have less of the larger HDL particles and more of the smaller HDL particles (6 9). One recent study has indicated that analysis of the subpopulation distribution of the plasma lipoproteins may be more predictive of occlusive disease than determination of the lipid concentrations (6). Characterizing the relationship between dyslipidemia and CVD has been the focus of a large body of research in recent years, with the goal of identifying those patients who are at a high risk of CVD development and providing a basis for therapeutic approaches. 62 OBESITY RESEARCH Vol. 8 No. 1 Jan. 2000
2 The risk and incidence of CVD is higher in obese patients with or without diabetes than lean patients of the same age (10,11). Patients with type 2 diabetes have a 4-fold higher risk of CVD than obese non-diabetics (11). This increase in CVD in patients with diabetes could be explained, in part, by changes in plasma lipid concentrations (12 14). We, and others, have also shown that there are differences in the subpopulation distribution of plasma lipoproteins that may predispose patients with diabetes to a higher risk for CVD. Patients with type 2 diabetes have a higher proportion of small and dense LDL and a lower proportion of larger HDL subfractions than non-diabetic controls (13,14). Thus, changes in the subpopulation distribution of plasma lipoproteins may contribute to the increased risk and incidence of CVD in patients with diabetes. African American (AA) women have a higher incidence of obesity (15,16) and diabetes (17), than white women. These elevated rates of obesity and diabetes are associated with an increased risk and incidence of vascular diseases (18,19) as in whites. However, African American women do not exhibit the aberrant lipid concentrations, to the same extent and frequency, that are thought to explain the relationship of obesity and diabetes to CVD, i.e., low HDL-C, high LDL-C, and high TG (20 24). Because the concentrations of the plasma lipids do not explain the higher CVD in obese and diabetic African American women, it is possible that this increase may result, partly, from alterations in the subpopulation distribution of the plasma lipoproteins. To date, there is a paucity of information on the subpopulation distribution of plasma lipoproteins in lean, obese, and diabetic African American women. Thus, this study was undertaken in order to address the following two aims. First: to determine if there are shifts in the subpopulation distribution of the lipoproteins toward more atherogenic profiles in obese and diabetic African American women. We determined the differences in the subpopulation distribution of plasma VLDL, LDL, and HDL, of lean, obese, and diabetic African American women. Second: to determine if the alterations in subpopulation distribution that accompany obesity and diabetes in African American women differ from those found with obesity and diabetes in white American (WA) women. We compared the lipoprotein profiles of lean, obese, and diabetic African American women to white counterparts. Determination of the subpopulation distribution was done by analysis of whole plasma by nuclear magnetic resonance (NMR) spectroscopy. In addition, we examined the activity of plasma cholesteryl ester transfer protein (CETP), a key enzyme in reverse cholesterol transport that has a role in shaping the lipoproteins in the plasma. Methods and Procedures Patient Characteristics and Treatment Fifty-one lean women (29 WA, 22 AA, body mass index [BMI] 30), 50 obese women (27 WA, 23 AA, BMI 30), and 43 obese women with type 2 diabetes (27 WA, 16 AA) participated in this study. Obese and diabetic subjects were recruited from patients examined in the Diabetes and Obesity Center at East Carolina University. Patients were not considered as potential participants if the physician noted complications other than obesity and/or diabetes (severe vascular problems, cancer, extreme emotional distress, etc.). Patients that were taking medications for hyperlipidemia and/or hypercholesterolemia were not included in the study. Lean subjects were recruited from faculty, staff, and students in the School of Medicine and were generally in good health. AA subjects in each group were stratified to subjects in the corresponding WA group, according to BMI. AA women were included in the study only if their parents and grandparents were of African American descent. Diagnosis of type 2 diabetes was based on the criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (25). Approximately 40% of diabetics were receiving treatment to help control blood glucose (sulfonylureas, insulin, etc.) at the time blood was collected. Body mass and height were recorded to the nearest 0.1 kg and 0.1 cm, respectively, and BMI was calculated (body weight in kg/(height in m) 2 ). Written consent was obtained from the patients after they were informed of the nature and potential risk of the study. The Institutional Review Board for human subject research approved the protocols used in this study. Plasma Analysis Blood was collected from the patients following a 12- hour fast, and a preservative mixture containing sodium azide (50 mg/ml) and aprotinin (1 TIU/mL) were added as preservatives (2 L/mL blood). Plasma was prepared by centrifugation at 1500g for 30 minutes at 4 C and stored at 80 C in aliquots until analyzed. Samples were analyzed spectrophotometrically for glucose (16-UV; Sigma Chemical Co., St. Louis, MO) and by microparticle enzyme immunoassay for insulin (IMx; Abbott Labs, Abbott Park, Il). CETP-specific cholesteryl ester transfer in the plasma was measured as the amount of [ 3 H]cholesteryl esters ( 3 H-CE; Dupont NEN) transferred from 3 H-CE HDL to apoprotein B-containing lipoproteins that could be inhibited by a human CETP-specific monoclonal antibody (TP2), as previously described (26). Lipid concentrations and lipoprotein subpopulation distributions were determined by NMR spectroscopy (6,27,28). As described by Freedman et al. (6), NMR analysis of lipoprotein subclasses is based upon each lipoprotein particle within a given diameter range exhibiting a distinct lipid NMR signal, the intensity of which is proportional to its bulk lipid mass concentration. NMR data are collected in three steps: 1) acquisition of the 250-MHz proton NMR spectra of the plasma sample; 2) deconvolution of the lipid methyl group signal envelope OBESITY RESEARCH Vol. 8 No. 1 Jan
3 appearing in these spectra at approximately 0.8 ppm, yielding signal amplitudes for 15 lipoprotein subclasses; and 3) conversion of the signal amplitudes into subclass concentrations with experimentally derived factors that are based upon chemically determined isolated subclass standards. The estimated diameters in nanometers for the 15 subclasses (six VLDL: V6, ; V5, 70 10; V4, 50 10; V3, 38 3; V2, 33 2; V1, 29 2; four LDL: IDL, 25 2; L3, ; L2, ; L1, ; five HDL: H5, ; H4, ; H3, ; H2, ; H1, ) have been previously reported (28). The 15 subclasses were then grouped into nine subclasses based upon the relationship of NMR subclasses to particle size estimates of gradient gel electrophoresis or electron microscopy measurements (28,29). The grouping of the subfractions are as follows: large VLDL (V6 V5), intermediate VLDL (V4), small VLDL (V3 V2 V1), large LDL (IDL L3), intermediate LDL (L2), small LDL (L1), large HDL (H5), intermediate HDL (H4 H3), and small HDL (H2 H1). Plasma lipids were calculated from subclass determinations. LDL particle concentration (LDL #) is calculated from the average size and the distribution data from LDL. HDL diff is a component of HDL lipoprotein subpopulation distribution that has a strong association with occlusive disease (6) and is calculated as large HDL intermediate HDL small HDL. Particle size for each class of lipoprotein was determined by weighting the relative percentage of each subclass by its diameter. Close agreement has been observed between chemically determined lipid concentrations and those determined with NMR (29). We confirmed these findings in a limited number of our patients (data not shown). LDL and HDL subclass determinations by gradient gel electrophoresis and NMR have also been closely related (28). In a limited number of patients, we also found that LDL size determined by NMR was closely correlated to LDL size determined from polyacrylamide gradient gel electrophoresis (PGGE) (r 0.77, p ). LDL size determined by NMR was approximately 15% lower than for our PGGE determinations, a consistent finding when comparing the two methods. The reason for this methodological difference is unknown. However, LDL size determinations by light scattering techniques also report LDL sizes considerably lower than those determined by PGGE, whereas results from the two methods correlate strongly (30). Oneal et al. (30) discuss some possibilities that may lead to the differences in absolute LDL size values. As a general reference, patients with the PGGE classification of the less atherogenic, type A profile have an NMR LDL size greater than 20.6 nm, whereas those with type B have an NMR LDL size less than 20.6 nm (NMR Lipoprofile; Lipomed, Raleigh, NC). Statistics The first objective of this paper was to determine if the subpopulation distribution in AA women is altered in obese and diabetic states, as has been shown in WA women. To achieve the first objective, data from each race was analyzed in separate one-way ANOVA models. Fisher s least significant difference post hoc test was used to determine differences between lean, obese, and diabetic groups. The second objective of this study was to determine if the alterations in lipoprotein subpopulation distribution found with obesity and diabetes differ between AA and WA women. To achieve the second objective, the data from both races were combined into a two-way ANOVA model to test for the main effects of group and race and the interaction between the two (group*race). Fisher s least significant difference (LSD) post hoc test was used to identify differences in group-related pairwise comparisons (lean vs. obese, obese vs. type 2, and lean vs. type 2). Results for general patient characteristics are expressed as means SEM. In that lean patients were observed to be younger than obese and type 2 groups, results for plasma lipids, lipoprotein subpopulation distribution, and CETP activity are expressed as age-adjusted means SEM, and analyses for these variables were conducted on age-adjusted residuals (Systat/SPSS, SPSS Inc., Chicago, IL). Results Table 1 shows the physical and biochemical characteristics of the subjects in this study. The results were generally similar for African and white Americans. In the combined analysis, the lean subjects were younger and had a lower body weight and BMI than the obese and type 2 groups. Fasting glucose levels in the type 2 were higher than in the obese and lean groups. Insulin levels were higher in the obese patients than in lean controls, and higher in type 2 than in both obese and lean patients. Table 2 shows the plasma lipid concentrations. In AA women, no differences were observed between lean, obese, and type 2 patients with respect to plasma lipid concentrations. In contrast, WA type 2 patients had elevated TC, LDL-C, LDL#, TG, and VLDL-TG, when compared to their lean and obese counterparts. When data from the patients were analyzed in a two-way model, LDL-C and LDL# were both elevated in obese and type 2 patients, when compared to lean. Furthermore, AA women had higher HDL-C, lower TG, and lower VLDL-TG, regardless of the presence of obesity and diabetes. The average lipoprotein particle sizes are also shown in Table 2. In AA, VLDL size was larger in type 2 women than in lean or obese groups. Trends for smaller LDL and HDL particle sizes were also observed in the type 2 group, although these differences did not meet the criteria for statistical significance. In WA, both obese and type 2 patients had larger VLDL and smaller HDL, when compared 64 OBESITY RESEARCH Vol. 8 No. 1 Jan. 2000
4 Table 1. Physical characteristics African American White American Lean Obese Type 2 Lean Obese Type 2 n Age (yr) a-1,3 32 1* Weight (kg) a-1, BMI (kg/m 2 ) a-1, Glucose (mm) a-2, Insulin (pm) a-1,2, * Values are shown as means SEM for each group (lean, obese, and diabetic) and race (AA and WA) combination. To examine the effects of obesity and diabetes in each race, data in each race were analyzed by separate one-way ANOVA models. Fisher s LSD post hoc test was used to test for differences in pairwise comparisons. Significantly different from corresponding lean subset (p 0.05). Type 2 subset significantly different from corresponding obese subset (p 0.05). To examine racial differences, the data from both races were combined into two-way ANOVA model. Statistical significance was inferred with p 0.05 for the main effect of group a. When a group effect a was observed, Fisher s LSD post hoc test was used to identify differences between the three categories (lean vs. obese a-1, obese vs. NIDDM a-2, and lean vs. NIDDM a-3 ). No variable showed a significant main effect of race or an interaction between group and race. to lean. Furthermore, LDL size was significantly smaller in type 2 patients when compared to lean patients. Consistent with these findings, a significant group effect was observed for all three of these parameters when data from the two races were combined in a two-way model. VLDL size was larger in obese patients than in lean, and even larger in type 2 patients, regardless of race. LDL size was smaller in type 2 patients, when compared to both lean and obese patients. HDL size was smaller in obese and type 2 patients, when compared to lean. No effect of race nor interaction between the factors of group and race were observed with the lipoprotein particle sizes. CETP activity (Table 2) was elevated in AA obese women when compared to lean and type 2 patients. This trend was also found in WA women. As expected, in a two-way model, obese women had elevated CETP activity compared to lean and type 2 women. Interestingly, AA women had higher CETP activity than WA women, regardless of the presence of obesity or diabetes. No interaction between the group and race effects was observed. Figure 1 shows the subpopulation distribution of VLDL in AA and WA women. In both races, large VLDL concentrations were higher in type 2 patients than in the lean subjects. In AA women, small VLDL-TG levels were higher in obese subjects when compared to lean group. In WA subjects, the type 2 group had a greater amount of intermediate VLDL-TG than both lean and obese groups. In the two-way model, WA women had higher concentrations of large, intermediate, and small VLDL-TG than AA women, regardless of obesity and diabetes (race effect, p 0.05). A group effect was only observed for large VLDL-TG concentrations (p 0.05), with type 2 patients having higher levels than obese and lean subjects (p 0.05). No interaction between the group and race effects (group*race) was observed for any parameter of VLDL subpopulation distribution in the two-way model. LDL subpopulation distribution is shown in Figure 2. In AA women, small LDL-C levels were higher in type 2 compared to lean and obese groups. In WA women, both intermediate and small LDL-C concentrations were higher in the type 2 patients than in obese and lean women. In the two-way model, a group effect was observed for small LDL-C, with statistical differences reflecting those found in the separate analyses (p 0.05). No race effect nor interaction between effects (group*race) was observed for any of the parameters of LDL subpopulation distribution. Figure 3 shows the subpopulation distribution of HDL. In AA women, large HDL-C concentrations were significantly lower in type 2 when compared to the lean group. Obese women had lower intermediate HDL-C concentrations than lean patients, but no differences were observed in small HDL-C concentrations between any of the three AA groups. In WA women, the concentration of large HDL-C were significantly lower in both obese and type 2 groups, when compared to the lean group. Obese women had higher concentrations of intermediate HDL than in lean, but no differences were observed in small HDL concentrations. HDL diff (Table 2), a parameter of HDL profiles that has a strong negative association with vascular disease, was lower in AA obese and type 2 women than in lean counterparts. OBESITY RESEARCH Vol. 8 No. 1 Jan
5 Table 2. Lipid concentrations, average lipoprotein particle sizes, and CETP activity African American White American Lean Obese Type 2 Lean Obese Type 2 n TC (mm) * LDL-C (mm) a-2, LDL# (nm) a-2, HDL-C (mm) b HDL diff (mm) c TG (mm) b VLDL-TG (mm) b VLDL size (nm) a-1,2, LDL size (nm) a-2, HDL size (nm) a-1, CETP (nmol/ml/h) a-1,2;b * Values are shown as age-adjusted means SEM for each group (lean, obese, and diabetic) and race (AA and WA) combination. LDL# is the concentration of LDL particles. HDL diff, a strong predictor of vascular disease, is calculated as large intermediate small HDL. Age-adjusted residuals were used in the analyses. To examine the effects of obesity and diabetes in each race, data in each race were analyzed by separate one-way ANOVA models. Fisher s LSD post hoc test was used to test for differences in pairwise comparisons. Significantly different from corresponding lean subset (p 0.05). Type 2 subset significantly different from corresponding obese subset (p 0.05). To examine racial differences, the data from both races were combined into a two-way ANOVA model. Data were analyzed by two-way ANOVA with age as a covariate. Statistical significance was inferred with p 0.05 for the main effects of group a, race b, and the interaction between the main effects c. When a group effect a was observed, Fisher s LSD post hoc test was used to identify differences between the three categories (lean vs. obese a-1 ; obese vs. type 2 a-2 ; and lean vs. type 2 a-3 ), using age-adjusted residuals. These differences were not observed in WA women. In the two-way model, both obese and type 2 patients had lower levels of large HDL-C than lean (p 0.05). For both intermediate HDL-C and HDL diff, an interaction between the main effects (group*race) was observed (p 0.05). Furthermore, AA women were observed to have a higher concentration of small HDL-C than WA women (race effect, p 0.05). Interestingly, the atherogenic alterations in the subpopulation distribution of VLDL, LDL, and HDL were closely related to plasma TG levels in WA women, whereas in AA women, these changes were more related to plasma glucose levels (data not shown). Discussion Although the increased rate of CVD in obese and diabetic WA subjects has been attributed, in part, to alterations in lipid concentrations, obese and diabetic AA subjects have elevated CVD without these perturbations. These observations have suggested that dyslipidemia in AA does not play a role in CVD risk. However, abnormal subpopulation distributions of the lipoproteins have also been related to CVD, and there are no reports of subpopulation distribution of lipoproteins in obese and diabetic AAs. Thus, we investigated the subpopulation distribution of the plasma lipoproteins in lean, obese, and diabetic women, selected from both the AA and the WA populations. Given that obesity is more severe in AA than WA (15,16), we stratified AA and WA patients in each group according to BMI, so that we could examine the relative contribution of adiposity to alterations in the subpopulation distribution in each race in the presence and absence of diabetes. As has been shown by other researchers using more traditional methods (21,22,24), AA women in this study tended to have higher HDL-C and lower TG, regardless of the level of obesity or presence of diabetes. Furthermore, although diabetic WA women appeared to exhibit more atherogenic lipid concentrations than their lean and obese counterparts, the lipid concentrations of diabetic AA women were relatively similar to those found in lean and obese AA women. In addition to confirming what has been found with respect to plasma lipid concentrations in AA and WA women, this study also supports our previous studies in WA subjects in which more traditional methods to determine lipoprotein subpopulation distribution were used. In the 66 OBESITY RESEARCH Vol. 8 No. 1 Jan. 2000
6 Figure 1. VLDL subpopulation distribution in lean, obese, and type 2 patients. Separate comparisons are shown for (A) African Americans and (B) white Americans. Values are shown as ageadjusted means SEM. To examine the effects of obesity and diabetes in each race, data in each race were analyzed by separate one-way ANOVA models. Fisher s LSD post hoc test was used to test for differences in pairwise comparisons. Significantly different from corresponding lean subset (p 0.05). Type 2 subset significantly different from corresponding obese subset (p 0.05). previous reports, we found smaller, more dense LDL and HDL in morbidly obese, diabetic women (13,14). This report extends our finding to include the changes in the subpopulation distribution of VLDL. The results of the present study show that VLDL subpopulation distribution is perturbed in severely obese, diabetic women, in that they have larger VLDL particles. Furthermore, it appears that similar atherogenic alterations in VLDL, LDL, and HDL profiles also occur to some extent in severely obese, WA women without diabetes. The novel findings of this study are that we observed atherogenic perturbations in VLDL, LDL, and HDL subpopulation distributions in the severely obese AA women, particularly those with type 2. AA diabetic women were Figure 2. LDL subpopulation distribution in lean, obese, and type 2 patients. Separate comparisons are shown for (A) African Americans and (B) white Americans. Values are shown as ageadjusted means SEM. To examine the effects of obesity and diabetes in each race, data in each race were analyzed by separate one-way ANOVA models. Fisher s LSD post hoc test was used to test for differences in pairwise comparisons. Significantly different from corresponding lean subset (p 0.05). Type 2 subset significantly different from corresponding obese subset (p 0.05). found to have larger VLDL particles, higher levels of small LDL-C, and lower levels of large HDL-C, than those found in lean women. Furthermore, HDL diff, which was reported to be a strong negative correlate of vascular disease (6), was lower in AA diabetic women than in lean counterparts. All of these alterations in lipoprotein profiles have been associated with vascular disease in other and/or combined populations (1 9) and may be contributing to the elevated disease rates in AA with type 2. In obese AA, potentially atherogenic perturbations in the subpopulation distribution were observed in an elevated small VLDL-TG, as well as in depressed HDL diff and intermediate HDL-C concentrations. OBESITY RESEARCH Vol. 8 No. 1 Jan
7 Figure 3. HDL subpopulation distribution in lean, obese, and type 2 patients. Separate comparisons are shown for (A) African Americans and (B) white Americans. Values are shown as age-adjusted means SEM. To examine the effects of obesity and diabetes in each race, data in each race were analyzed by separate one-way ANOVA models. Fisher s LSD post hoc test was used to test for differences in pairwise comparisons. Significantly different from corresponding lean subset (p 0.05). Lipoprotein particles tended to be more atherogenic than in the lean group, but these tendencies were not as severe as was found in the type 2 group. These data indicate that alterations in the subpopulation distribution of the lipoproteins in obese and type 2 women of AA descent may be contributing to the elevated risk for vascular disease in these abnormal physiological states. Furthermore, particularly in AA women, the subpopulation distribution of the lipoproteins have better clinical markers to identify high risk patients than the commonly used lipid concentrations. In addition to reporting the alterations in lipoprotein subpopulation distribution in AA women that occur with obesity and diabetes, we were also able to compare the alterations that occur in WA counterparts. Reflecting their lower TG and higher HDL-C concentrations, all subfractions of VLDL were lower, and small HDL-C levels were higher, in AA women. Although the atherogenic perturbations in particle size and subpopulation distribution of the lipoproteins in obese and type 2 women were generally similar for AA and WA women, our data suggest that subtle racial differences may exist. Most striking, the effects of obesity and diabetes regarding intermediate HDL-C and HDL diff were significantly different for AA and WA women. Our data also suggest that there are more subtle racial differences in how obesity and diabetes affected the concentrations of intermediate and small VLDL-TG and intermediate LDL-C concentrations. Although these racial differences are interesting, it is difficult to interpret the significance of these findings without further studies. We are unaware of any large, well-controlled studies that suggest different rates of vascular disease in AA and WA women. From a practical standpoint, however, these racial differences may suggest that race-specific criteria are needed in the clinical setting to better identify patients at high risk for vascular disease. In this respect, studies investigating how these subpopulation distribution parameters relate to vascular disease in race-specific populations are warranted. These studies are particularly important for the AA population, as these parameters of subpopulation distribution may be found to be markedly more predictive of vascular disease than lipid concentrations alone. Although we did not extensively examine the mechanisms behind the racial differences in the subpopulation distribution of the lipoproteins, we speculate that they may be related to the variations in the plasma enzymes known to modulate the composition of lipoproteins. Lipoprotein lipase (LPL), an enzyme that clears TG from plasma to the peripheral tissues, has been shown to be higher in a subset of the AA population when compared to a comparable WA subset (31). If this difference persists between all subset comparisons, the AA population may have lower TG due to an increased ability to clear TG from the plasma. LPL also has been shown to be depressed in diabetics and may account for the elevation in TG in our diabetic WA patients (32). This idea warrants further investigation as we did not measure LPL in our patients. A complimentary explanation could be derived from the comparison of plasma CETP activity in WA and AA observed in each patient group. Although CETP is primarily known for its putative role in at least one arm of reverse cholesterol transport pathway (33), it also clears TG from VLDL by transporting it to HDL. These TG eventually end up in the liver by the action of hepatic triglyceride lipase (HL). Altered expression of all three of these enzymes, LPL, CETP, and HL, contributes to 68 OBESITY RESEARCH Vol. 8 No. 1 Jan. 2000
8 the remodeling of the lipoproteins and may mediate the effects of obesity and diabetes on lipoprotein subpopulation distribution (32,34,35). It should be noted that the number of patients examined in this study is relatively small for the amount of variability that is usually found in human studies. In that patient inclusion was affected by a number of potentially complicating variables, the confirmation of our findings in a larger, population-based study is warranted. Furthermore, the patients that we examined were severely obese, and observing how obesity and diabetes affect lipoprotein subpopulation distribution, as well as how racial differences are manifested, in overweight and mildly obese individuals would be of interest. Likewise, similar investigations in men, in whom vascular disease rates are higher, would be warranted. Even in light of the limitations and the number of questions raised by our study, this initial look at subpopulation distribution of the lipoproteins in AA women may have clinical relevance now that determining lipoprotein profiles by NMR is commercially available to physicians. In summary, our data suggest that severely obese AA women, particularly those with diabetes, have perturbations in the lipoprotein subpopulation distributions that imply an increased risk for vascular disease. Interestingly, these alterations were not accompanied by drastically perturbed lipid concentrations, as is frequently found in other populations. These findings suggest that, in AA women, lipoprotein subpopulation distribution parameters may be more effective in predicting vascular disease than lipid concentrations alone. Although the alterations in lipoprotein subpopulation distributions found in obesity and type 2 were generally similar for AA and WA women, subtle racial differences did exist, particularly with respect to HDL. These observations suggest that the criteria for predicting vascular disease may need to be race-specific. Given the prevalence of obesity and diabetes in AA and the substantial health care costs that are involved in treating vascular disease in these patients, studies designed to clarify the relationship between lipoprotein subpopulation distribution and vascular disease in the AA population are warranted. Acknowledgments We thank Dr. Jim Otvos in the Department of Biochemistry at North Carolina State University for assistance in the processing and interpretation of NMR data. This work was supported by a grant from the National Institutes of Health (Department of Health and Human Services Public Health Service DK 45029). References 1. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260: Campos H, Genest JJ Jr, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12: Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276: Griffin BA, Freeman DJ, Taait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106: Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276: Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18: Wilson HM, Patel JC, Russe D, Skinner ER. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma of high density lipoprotein in coronary heart disease. Clin Chim Acta. 1993;220: Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb. 1991; 11: Laakso M, Voutilainen E, Pyörälä K, Sarlund H. Association of low HDL and HDL 2 cholesterol with coronary heart disease in noninsulin-dependent diabetics. Arteriosclerosis. 1985; 5: Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease. N Engl J Med. 1990;322: Abbott RD, Donahue RP, Kannel WB, Wilson WF. The impact of diabetes on survival following myocardial infarction in men vs. women. JAMA. 1988;260: Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;24: Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, Marks R. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes. 1990;39: Barakat HA, McLendon VD, Marks R, Pories W, Heath J, Carpenter JW. Influence of morbid obesity and non-insulindependent diabetes mellitus on high-density lipoprotein composition and subpopulation distribution. Metabolsim. 1992;41: Dawson DA. Ethnic differences in female overweight: data from the 1985 National Health Interview Survey. Am J Public Health. 1988;129: Kuczmarski RJ, Flegel KM, Campbell SM, Johnson CL. Increased prevalence of overweight among U.S. adults. The National Health & Nutrition Examination Survey to JAMA. 1994;272: OBESITY RESEARCH Vol. 8 No. 1 Jan
9 17. Lipton RB, Liao Y, Cao G, Cooper RS, McGee D. Determinants of incident non-insulin dependent diabetes mellitus among blacks and whites in a national sample: The NHANES I Epidemiological Follow-up Study. Am J Epidemiol. 1993; 138: Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Am J Epidemiol. 1998;148: Tull ES, Roseman JM. Diabetes in African Americans. In: Diabetes in America, 2nd ed. Bethesda, MD: National Institutes of Health; 1995: Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of upper body obesity. Diabetes. 1993;42: Cowie CC, Howard BV, Harris MI. Serum lipoproteins in African-Americans and whites with non-insulin dependent diabetes in the US population. Circulation. 1994;1690: Conway JM, Yanovski SZ, Avila NA, Hubbard VS. Visceral adipose tissue differences in black and white women. Am J Clin Nutr. 1995;61: Gaillard TR, Schuster DP, Bossetti BM, Green PA, Osei K. The impact of socioeconomic status on cardiovascular risk factors in African-Americans at high risk for type II diabetes. Diabetes Care. 1997;20: Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-related health risks in obese nondiabetic premenopausal women. Diabetes. 1997;46: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20: Vadlamudi S, MacLean P, Green T, et al. Role of female sex steroids in regulating cholesteryl ester transfer protein in transgenic mice. Metabolism. 1998;47: Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38: Otvos, JD. Measurement of lipoprotein subclass profiles by NMR spectroscopy. In: Rifai et al., eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997, pp Otvos J, Jeyarajah E, Bennett D. A spectroscopic approach to lipoprotein subclass analysis. J Clin Ligand Assay. 1996; 19: O Neal D, Harrip P, Dragicevic G, Rae D, Best JD. A comparison of LDL size determination using gradient gel electrophoresis and light scattering methods. J Lipid Res. 1998;39: Ama PFM, Poehlman ET, Simoneau JA, et al. Fat distribution and adipose tissue metabolism in nonobese male black African and Caucasian subjects. Int J Obes. 1986;10: Taskinen MR, Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin dependent diabetes. Arteriosclerosis. 1988;8: Bruce C, Chouinard RA, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998;18: Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 1994;24: Syvanne M, Ahola M, Lahdenpera S, et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res. 1995;36: OBESITY RESEARCH Vol. 8 No. 1 Jan. 2000
Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationMeasurement of Trigly ceride-rich Lipoproteins by Nuclear Magnetic Resonance Spectroscopy
Clin. Cardiol. Vol. 22 (Suppl. 11), 11-21-11-27 (1999) Measurement of Trigly ceride-rich Lipoproteins by Nuclear Magnetic Resonance Spectroscopy JAMES CII'VOS, PH.D. Department of Biochemistry, North Carolina
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationPREDIABETES TESTING SERVICES
PREDIABETES TESTING SERVICES ASSESSING DIABETES RISK IN ASYMPTOMATIC ADULTS Depending upon population characteristics, up to 70% of individuals with prediabetes will ultimately progress to diabetes at
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationLDL SUBCLASS PATTERNS AND ATHEROGENICITY IN NON-INSULIN DEPENDENT DIABETES MELLITUS
LDL SUBCLASS PATTERNS AND ATHEROGENICITY IN NON-INSULIN DEPENDENT DIABETES MELLITUS F. Kazerouni *1, E. Javadi 1, M. Doosti 1 and B. Larijani 2 1) Department of Medical Biochemistry, School of Medicine,
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationThe insulin resistance syndrome (IRS) is a trait
Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance W. Timothy Garvey, 1,2 Soonho Kwon, 1 Deyi Zheng, 3 Sara
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationCARDIO Test INFAI. for Cardiac Risk Assessment
CARDIO Test INFAI for Cardiac Risk Assessment Heart Attack and Stroke: A Worldwide Problem NMR analysis of serum to assess the risk of cardiovascular disease Headquarter in Cologne (RTZ) Facility in Bochum
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More informationORIGINAL INVESTIGATION. Fasting Triglyceride and the Triglyceride HDL Cholesterol Ratio Are Not Markers of Insulin Resistance in African Americans
ORIGINAL INVESTIGATION Fasting Triglyceride and the Triglyceride HDL Cholesterol Ratio Are Not Markers of Insulin Resistance in African Americans Anne E. Sumner, MD; Karl B. Finley, MD; David J. Genovese,
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationRole of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC
J Cardiol 2000 ; 36: 371 378 Small Dense Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels Shinji Tsutomu Taro Keiko Takeshi Minoru Hiroshi
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationMeasurement of Small Dense Low-density Lipoprotein Particles
67 Journal of Atherosclerosis and Thrombosis Reviews Vol. 12, No. 2 Measurement of Small Dense Low-density Lipoprotein Particles Tsutomu Hirano 1, Yasuki Ito 2, and Gen Yoshino 3 1 Division of Diabetes
More informationWalter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI
Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides
More informationThe Metabolic Syndrome Maria Luz Fernandez, PhD
June 2007(II): S30 S34 The Metabolic Syndrome Maria Luz Fernandez, PhD The metabolic syndrome is a cluster of symptoms associated with insulin resistance and known to precede the onset of type 2 diabetes.
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationLipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women
Diabetes Publish Ahead of Print, published online February 25, 2010 Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women Samia Mora, MD, MHS,
More informationEffect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size
Atherosclerosis 180 (2005) 127 135 Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size Paolo M. Suter a,, Gabrielle Marmier a, Caroline Veya-Linder b, Edgar
More informationRelationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome
ORIGINAL INVESTIGATION Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome Jacob J. Clarenbach, Scott M. Grundy, Natalia Palacio, and Gloria Lena Vega Low-density
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.115 Evaluation of Carotid Intima
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationMetabolic defects underlying dyslipidemia in abdominal obesity
Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/
More informationLipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes
Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes 2 Michael Cobble, Patrick D. Mize, and Eliot A. Brinton Insulin Resistance and Type 2 Diabetes The pathophysiology of
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationDownloaded from journal.bums.ac.ir at 23:16 IRST on Saturday February 16th 2019
( ) - - - - :.. - : HDL-C.. ( )... P / t () : (P
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationInternational Journal of Pharma and Bio Sciences
Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 CORRELATION BETWEEN SERUM URIC ACID LEVELS AND NON HDL CHOLESTEROL IN TYPE II DIABETES MELLITUS AN OBSERVATIONAL
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationLipid profile in Diabetes Mellitus
Original Research Shankarprasad DS 1,*, Shivanand Gundalli 2, Mahantesh B 3, SV Kashinakunti 4, Sunitha P 5 1,4 Professor, 3 Postgradute student, 5 Associate Professor, Department of Biochemistry, 2 Assistant
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationANTHROPOMETRIC CHARACTERISTICS OF SOME LIMB AND BODY CIRCUMFERENCES IN MALES AND FEMALES WITH TYPE 2 DIABETES MELLITUS
PROCEEDINGS OF THE BALKAN SCIENTIFIC CONFERENCE OF BIOLOGY IN PLOVDIV (BULGARIA) FROM 19 TH TILL 21 ST OF MAY 2005 (EDS B. GRUEV, M. NIKOLOVA AND A. DONEV), 2005 (P. 159 164) ANTHROPOMETRIC CHARACTERISTICS
More informationAtherogenic Lipoprotein Profile in Families with and without History of Early Myocardial Infarction
Physiol. Res. 50: 1-8, 2001 Atherogenic Lipoprotein Profile in Families with and without History of Early Myocardial Infarction M. DOBIÁŠOVÁ 1, K. RAŠLOVÁ 2, H. RAUCHOVÁ 1, B. VOHNOUT 2, K. PTÁČKOVÁ 1,
More informationAsubstantial minority of adults and adolescents
THE METABOLIC SYNDROME AS A RISK FACTOR FOR TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE Roger S. Blumenthal, MD* ABSTRACT This paper discusses the prevalence and clinical significance of the metabolic syndrome
More informationSupplementary Note Details of the patient populations studied Strengths and weakness of the study
Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationCoverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests
Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationType 1 diabetes is associated with an increased
Lipoprotein Subclasses and Particle Sizes and Their Relationship With Coronary Artery Calcification in Men and Women With and Without Type 1 Diabetes Helen M. Colhoun, 1 James D. Otvos, 2 Mike B. Rubens,
More informationResponses of blood lipids to aerobic and resistance type of exercise
Responses of blood lipids to aerobic and resistance type of exercise Labros Sidossis, Ph.D. Laboratory of Nutrition and Clinical Dietetics Harokopio University of Athens, Greece Triacylglycerol structure
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationARIC Manuscript Proposal # 979. PC Reviewed: 11/21/03 Status: Rejected Priority: SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 979 PC Reviewed: 11/21/03 Status: Rejected Priority: SC Reviewed: Status: Priority: 1.a. Full Title: Factors of the metabolic syndrome and incidence of coronary heart disease,
More informationEvaluation of Anthropometric Indices of Patients with Left Ventricle Dysfunction Fallowing First Acute Anterior Myocardial Infarction
Journal of Cardiovascular and Thoracic Research, 2012, 4(1), 11-15 doi: 10.5681/jcvtr.2012.003 http://jcvtr.tbzmed.ac.ir Evaluation of Anthropometric Indices of Patients with Left Ventricle Dysfunction
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationHi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy.
LIPID CASE 251 Treating HDL Size Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy. I was asked about a 44 year old physically
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More informationNuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study
Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study Lewis Kuller, Alice Arnold, Russell Tracy, James Otvos, Greg Burke, Bruce Psaty,
More informationDiabetes and Decline in Heart Disease Mortality in US Adults JAMA. 1999;281:
ORIGINAL CONTRIBUTION and Decline in Mortality in US Adults Ken Gu, PhD Catherine C. Cowie, PhD, MPH Maureen I. Harris, PhD, MPH MORTALITY FROM HEART disease has declined substantially in the United States
More informationEffects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.
Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:
More informationClinical Investigation and Reports
Clinical Investigation and Reports Effect of 7-Year Infancy-Onset Dietary on Serum Lipoproteins and Lipoprotein Subclasses in Healthy Children in the Prospective, Randomized Special Turku coronary Risk
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationPattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus
Original Article Nepal Med Coll J 2012; 14(4): 278-282 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus A
More informationImpact of Chronicity on Lipid Profile of Type 2 Diabetics
Impact of Chronicity on Lipid Profile of Type 2 Diabetics Singh 1, Gurdeep & Kumar 2, Ashok 1 Ph.D. Research Scholar, Department of Sports Science, Punjabi University Patiala, India, Email: drgurdeep_sahni@yahoo.co.in
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationInternational Journal of Clinical and Biomedical Research Original Article
ISSN: 2395-0471 International Journal of Clinical and Biomedical Research Original Article STUDY OF HbA1c AS A BIOMARKER IN DYSLIPIDEMIA AND ATHEROGENICITY IN TYPE 2 DIABETES MELLITUS *TIWARI RAJLAXMI
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition
More informationNOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE
CARDIOVASCULAR DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationStudy of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases
Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationAssociation between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus
Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus Sophie Bernard, Philippe Moulin, 1 Laurent Lagrost,* Sylvie Picard,
More informationDownloaded from ijdld.tums.ac.ir at 19:13 IRDT on Friday May 4th 2018
- : -. : - 3 *. () - :.. 30 608 43 : (LDL-C) (HDL-C) TG/HDL-)HDL-C TG (TC/HDL-C)HDL-C (HRs) TC (non- HDL-C) (TG) (TC) HDL. 8/4. HR. ( 98 9). TG/HDL-C (C 89 : HDL-C.[/3 (/0 -/57)] TC/HDL-C. ( C ) WHO non-hdl-
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAN ABSTRACT OF THE THESIS OF
AN ABSTRACT OF THE THESIS OF Ye-Sun Lee for the degree of Doctor of Philosophy in Nutrition and Food Management presented on September 21, 1999. Title: The Effect of Supplementation with n-9, n-6, and
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationLDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) :
197-207 (2 ) 10 1389 -. 2 1 1* :.. 352 :... (TG). (). -.(r= 0/95) :. TG. NCEP-ATP-III. :. () : -1-2 1593748711 : ronakn2000@yahoo.com : 88942661-5 09124135284 ... : 198.[4]. 1990 -. C.[4]. NCEP.[4]...
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationHBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS
Original Article HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS Chintamani Bodhe*, Deepali Jankar**, Tara Bhutada***, Milind Patwardhan****, Mrs Varsha Patwardhan***** ABSTRACT
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More information